Skip to Main Content
Our Commitment to Diversity

REPRESENTATIVE EXPERIENCE

Whitney J. Smith

Represented consumer finance company OneMain Financial in its acquisition of Trim, a financial wellness company based in California that empowers customers across the United States to manage their financial goals by negotiating bills, analyzing transaction data, and enabling automated savings.
Represented Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, in connection with the issuance of approximately US$27.5 million aggregate principal amount of Series D Zero Coupon Convertible Senior Notes due 2023. The new Series D Convertible Notes were issued in exchange for approximately US$57.9 million in aggregate principal amount, plus accrued but unpaid interest, of the company’s outstanding 4.75 percent Series A Convertible Senior Notes due May 2023, which gave effect to a 52.5 percent discount on the principal amount of Series A Convertible Notes exchanged.
Represented Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, in a series of strategic actions to enhance the company's financial flexibility. To reduce leverage, the company worked with its senior lender and Series C Convertible Noteholders to convert US$77 million of debt into a combination of common and preferred stock. The lenders also provided an additional US$4.6 million of availability under the company's second lien credit facility. Upon consummating the debt conversion and incremental debt financing, the company launched an at-the-market equity offering seeking to raise an additional US$22.6 million.

Represented Par Pharmaceuticals, in connection with its bid to acquire Somerset Therapeutics, a sterile injectible business, and its affiliate Wintac Limited, a Bangalore, India-based CDMO listed on the Bombay Stock Exchange (terminated due to lack of timely regulatory approval).

Represented Par Pharmaceuticals in its acquisition of Innoteq, a developer and manufacturer of transdermal patch and thin film pharmaceutical products.

Represented Par Pharmaceuticals in its acquisition of Edict Pharmaceuticals, an India-based R&D pharmaceutical company.

Represented Par Pharmaceuticals in connection with the divestiture of its North Carolina and Alabama manufacturing facilities and related generic pharmaceutical products.

Represented Par Pharmaceuticals, in its acquisition of Nuray Chemicals Private Limited, an India-based developer and manufacturer of API.

Represented Par Pharmaceuticals in its acquisition of Ethics Bio Lab Pvt. Ltd., a contract research organization that provides bioavailability and bioequivalence studies.

Advised NYSE-listed company in connection with a significant restatement of past financial statements and related SEC and NYSE inquiries.

Acquisition of a basket of 14 products in an FTC-mandated divestiture related to Watson Pharmaceuticals’ acquisition of Actavis.
Represented Erie Street Capital in its acquisition (together with its acquisition partner PSP Capital Partners) of 3Q Digital, a performance & digital marketing agency.
Represented Erie Street Consulting in its acquisition of Performance Improvement Partners, a business process and IT management solutions firms serving PE firms and their portfolio companies.

Represented speciality pharmaceutical company Mayne Pharma in its acquisition of six branded foam dermatology products from GSK.

Represented Mayne Pharma in its acquisition of 42 generic products in an FTC-mandated divestiture related to Teva’s acquisition of Allergan’s generic pharmaceutical business.

Represented Engine Group, a portfolio company of Lake Capital, in its acquisition of bRealTime, a supply-side digital advertising technology company that helps publishers monetize inventory through real-time bidding exchanges.

Represented Engine Group, a portfolio company of Lake Capital, in its acquisition of Clearstream.tv, a demand-side digital advertising technology company.

Represented Engine Group, a portfolio company of Lake Capital, in its acquisition of Balihoo, a provider of digital advertising technology enabling national brands to execute hyper-local campaigns.

Represented Fotmer Life Sciences, a Canadian company with operations in Uruguay and the first government license to grow and export medical cannabis in Uruguay, in its international corporate structuring and Series A and Series B equity financings.

Represented Crane Co., a diversified manufacturer of industrial products, in its acquisition of Westlock Controls, a a manufacturer of switchboxes, position transmitters and other solutions for networking, monitoring and controlling process valves.

Represented VitAg, a company that had developed technology to manufacture fertilizer from biosolids, in its management buyout and subsequent restructuring involving an equity investment by TPG, a tax-exempt bond offering, a credit facility and a real estate purchase for the purpose of constructing and commissioning its first biosolids-to-fertilizer plant.

Represented Solvay, a global chemical company, in the divestiture of its formulated resins business.

Represented the London Stock Exchange Group in its acquisition of Bonds.com, a publicly traded U.S. broker-dealer.

Represented Wilson Towers Watson in its divestiture of multiple offices and insurance brokerage businesses.

Advised Artesyn Technologies, a power solutions company listed on Nasdaq, and its Board of Directors in connection with an unsolicited proposal to merge the company and subsequently in connection with negotiations with an activist hedge fund that had acquired a 10% stake in the company.

Represented Philips in its acquisition of Raytel Medical Corporation, a U.S. remote cardiac monitoring company from an Israeli telemedicine company.

Represented Philips in its acquisition of Lighting Technologies International, a specialty lighting company.

Represented Philips in its acquisition of Digital Lifestyle Outfitters, an electronics peripherals and accessories distribution company.

Represented generic pharmaceutical company Teligent in its $34.4 million Series B Senior Convertible Notes offering.

Represented generic pharmaceutical company Teligent in its $50 million Series C Convertible Note Financing and Exchange.

Represented DuPont in its acquisition of a provider of sulfuric acid technology processes and equipment from PE firm American Securities.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel